Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly & Co. tapped the US investment-grade ... company sold $6.5 billion of bonds in six parts, according to a person familiar with the matter. The longest portion of the deal, a 40-year ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Both treatments mimic certain gut hormones to tamp down a person's appetite and regulate their blood sugar. The popularity of those injectable drugs has forced both Eli Lilly and its rival Novo ...

Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...